Efficacy and Safety of MIL62, a Glycoengineered Type II Anti-CD20 Antibody, in Primary Membranous Nephropathy: A Phase 3, Randomized, Controlled Trial

Zhao Cui, Min Wei, Peng Li, Rong Wang, Heng Li, Haitao Zhang, Hong Lin, Chen Xiao Lan, Ping Luo, Hua Zhou, Guangqun Xing, Guisen Li, Yuehong Li, Wei Chen, Junjun Zhang, Yu Chen, Wei Liang, Qiongqiong Yang, Hui Zheng, Hua Li, Yanning Zhang, Zhaohui Ni, Xu Hui, Xing Chen, Ming ZhaoJournal of the American Society of Nephrology 2025 · DOI

BibTeX
@article{cui2025efficacy,
  author = {Zhao Cui and Min Wei and Peng Li and Rong Wang and Heng Li and Haitao Zhang and Hong Lin and Chen Xiao Lan and Ping Luo and Hua Zhou and Guangqun Xing and Guisen Li and Yuehong Li and Wei Chen and Junjun Zhang and Yu Chen and Wei Liang and Qiongqiong Yang and Hui Zheng and Hua Li and Yanning Zhang and Zhaohui Ni and Xu Hui and Xing Chen and Ming Zhao},
  title = {{Efficacy and Safety of MIL62, a Glycoengineered Type II Anti-CD20 Antibody, in Primary Membranous Nephropathy: A Phase 3, Randomized, Controlled Trial}},
  journal = {Journal of the American Society of Nephrology},
  year = {2025},
  doi = {10.1681/asn.202564sha3em},
}

Loading related content...

Figure